1. Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels Among Statin Treated Adults With Cardiovascular Disease
- Author
-
Wong, Nathan D, Zhao, Yanglu, Sung, Jennifer, and Browne, Auris
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Patient Safety ,Cardiovascular ,Aging ,Clinical Research ,Heart Disease ,Atherosclerosis ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Good Health and Well Being ,Acute Coronary Syndrome ,Aged ,Cardiovascular Diseases ,Cholesterol ,LDL ,Coronary Disease ,Female ,Hospitalization ,Humans ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Ischemic Stroke ,Lipoprotein(a) ,Male ,Middle Aged ,Myocardial Infarction ,Myocardial Revascularization ,Prognosis ,Proportional Hazards Models ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
The relation between elevated lipoprotein(a) and total atherosclerotic cardiovascular disease (ASCVD) residual risk in persons with known cardiovascular disease on statin therapy is not well-established. We examined first and total recurrent ASCVD event risk in statin-treated adults with prior ASCVD. We studied 3,359 adults (mean age 63.6 years, 85.1% male) with prior ASCVD on statin therapy from the AIM-HIGH clinical trial cohort. The first and total ASCVD event rates were calculated by lipoprotein(a) [Lp(a)] categories. Cox regression and Prentice, Williams and Peterson (PWP) models provided hazard ratios (HRs) for ASCVD events over a mean follow-up of 3.3 years, adjusted for age, gender, trial treatment, LDL-C, and other risk factors. A total of 747 events occurred during follow-up, among which 544 were first events. First and total ASCVD event rates were greater with higher Lp(a) levels. Compared with Lp(a)
- Published
- 2021